FDA-approved Alzheimer’s drug distribution despite opposition from many experts in the United States

WONOSOBO NEWS – Food and Drug Administration (FDA) America The United States on Monday, June 6, 2021 approved the circulation of drugs for the disease Alzheimer although it is still under debate.

The decision FDA it is much opposed by some experts Alzheimer who said that there was not enough evidence the drug could help patients.

“The data included in the application is very complex and explains the uncertainty about clinical benefits,” writes Dr. Patrizia Cavazzoni in website FDA.

Also Read: There are no Magnetic Microchip Particles in Vaccines, Confirmation from the Covid-19 Task Force

At the heart of this drug controversy involves two Phase 3 trials with conflicting results.

Some argue that the drug may slow cognitive decline, but other trials have shown no benefit in the drug.

The trial was discontinued because more than a third of the 3,285 trial participants did not show significant results.

Also Read: Pfizer and Moderna Covid-19 Vaccines have not been used in Indonesia, here are the reasons for the Indonesian government

Obat Aducanumab who will use the brand Aduhelm in the treatment of Alzheimer’s is a monthly intravenous infusion intended to slow cognitive decline in people with thinking memory problems.

– .